Skip to main content

Table 5 Multivariate analysis of risk factors associated with neonatal adverse effects

From: Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study

Risk Factors

Birth weight

Relative Risk

Logistic Regression

Gestational age at birth

Relative Risk

Logistic Regression

Anemia

Relative Risk

Logistic Regression

Hepatic alterations

Relative Risk

Logistic Regression

<2500 g

>=2500 g

  

<37 weeks

>=37 weeks

Yes

No

Yes

No

n

%

n

%

RR CI 95%

RR CI 95%

n

%

n

%

RR CI 95%

RR CI 95%

n

%

n

%

RR CI 95%

RR CI 95%

n

%

n

%

RR CI 95%

RR CI 95%

Maternal age

 <=28 yrs

84

47.2

332

54.1

1

 

102

54.0

312

52.2

1

 

104

56.2

270

50.2

1

 

63

49.2

104

46.2

1

 

 >28 yrs

94

52.8

282

45.9

1.24 (0.92–1.66)

 

87

46.0

286

47.8

0.95 (0.71–1.26)

 

81

43.8

268

49.8

0.84 (0.62–1.12)

 

65

50.8

121

53.8

0.93 (0.66–1.31)

 

Hypertension

 No

157

88.7

583

95.6

1

 

175

93.1

562

94.6

1

 

181

97.8

499

93.4

1

 

120

94.5

212

94.6

1

 

 Yes

20

11.3

27

4.4

2.01 (1.26–3.20)

 

13

6.9

32

5.4

1.22 (0.69–2.14)

 

4

2.2

35

6.6

0.39 (0.14–1.04)

 

7

5.5

12

5.4

1.02 (0.48–2.18)

 

 No information

1

 

4

   

1

 

4

     

4

   

1

 

1

   

Diabetes during pregnancy

 No

160

94.7

523

93.4

1

 

168

96.0

511

93.1

1

 

160

94.7

469

93.2

1

 

106

93.8

212

95.1

1

 

 Yes

9

5.3

37

6.6

0.84 (0.43–1.64)

 

7

4.0

38

6.9

0.63 (0.30–1.34)

 

9

5.3

34

6.8

0.82 (0.42–1.61)

 

7

6.2

11

4.9

1.17 (0.54–2.51)

 

 No information

9

 

54

   

14

 

49

   

16

 

35

   

15

 

2

   

Coinfection during pregnancy

 No

19

10.7

96

15.8

1

 

24

12.8

91

15.3

1

 

26

14.1

79

14.8

1

 

22

17.3

31

13.9

1

 

 Yes

158

89.3

513

84.2

1.42 (0.89–2.29)

 

163

87.2

503

84.7

1.17 (0.76–1.80)

 

159

85.9

454

85.2

1.05 (0.69–1.59)

 

105

82.7

192

86.1

0.86 (0.54–1.35)

 

 No information

1

 

5

   

2

 

4

   

0

 

5

   

1

 

2

   

Smoking

 No

88

77.2

362

87.7

1

 

104

85.2

341

85.3

1

 

115

90.6

288

83.2

1

 

70

83.3

61

69.3

1

 

 Yes

26

22.8

51

12.3

1.73 (1.12–2.67)

 

18

14.8

59

14.8

1 (0.57–1.65)

 

12

9.4

58

16.8

0.6 (0.33–1.09)

 

14

16.7

27

30.7

0.64 (0.36–1.13)

 

 No information

64

 

201

   

67

 

198

   

58

 

192

   

44

 

137

   

Substance abuse

 No

95

78.5

381

87.4

1

 

111

86.0

360

85.1

1

 

121

90.3

304

82.8

1

 

75

80.6

66

61.7

1

1

 Yes

26

21.5

55

12.6

1.61 (1.04–2.48)

 

18

14.0

63

14.9

0.94 (0.57–1.55)

 

13

9.7

63

17.2

0.6 (0.34–1.07)

 

18

19.4

41

38.3

0.5 (0.34–0.96)

0.47 (0.27–0.83)

 No information

57

 

178

   

60

 

175

   

51

 

171

   

35

 

118

   

Alcoholism

 No

98

92.5

388

94.9

1

 

113

95.8

368

93.9

1

 

123

96.9

312

92.9

1

 

79

95.2

69

81.2

1

 

 Yes

8

7.5

21

5.1

1.37 (0.67–2.81)

 

5

4.2

24

6.1

0.73 (0.30–1.80)

 

4

3.1

24

7.1

0.51 (0.19–1.37)

 

4

4.8

16

18.8

0.38 (0.14–1.02)

 

 No information

72

 

205

   

71

 

206

   

58

 

202

   

45

 

140

   

First CD4 (cells/mm3)

 <200

31

18.0

59

10.5

1

 

34

19.2

55

9.9

1

 

24

13.8

59

11.7

1

 

20

17.1

21

9.6

1

 

 >=200

141

82.0

505

89.5

0.64 (0.43–0.94)

 

143

80.8

499

90.1

0.58 (0.40–0.85)

 

150

86.2

444

88.3

0.87 (0.57–1.34)

 

97

82.9

198

90.4

0.67 (0.42–1.09)

 

 No information

6

 

50

   

12

 

44

   

11

 

35

   

11

 

6

   

Peripartum CD4 (cells/mm3)

 <200

30

17.5

47

8.36

1

1

32

18.2

44

8.0

1

1

21

12.1

50

9.9

1

 

18

15.5

18

8.2

1

 

 >=200

141

82.5

515

91.6

0.55 (0.37–0.82)

0.47 (0.29–0.77)

144

81.8

508

92.0

0.53 (0.36–0.77)

0.54 (0.37–0.79)

152

87.9

453

90.1

0.85 (0.54–1.34)

 

98

84.5

201

91.8

0.6 (0.40–1.08)

 

 No information

7

 

52

   

13

 

46

   

12

 

35

   

12

 

6

   

Peripartum viral load

 Undetectable (<50 copies/ml)

92

54.8

343

60.4

1

 

99

56.3

336

60.5

1

 

106

60.9

302

59.7

1

 

58

49.2

168

76.0

1

1

 Detectable (>=50 copies/ml)

76

45.2

225

39.6

1.19 (0.88–1.62)

 

77

43.8

219

39.5

1.14 (0.85–1.54)

 

68

39.1

204

40.3

0.96 (0.71–1.31)

 

60

50.8

53

24.0

2.61 (1.44–2.97)

2.37 (1.52–3.68)

 No information

10

 

46

   

13

 

43

   

11

 

32

   

10

 

4

   

CDC classification

 1

47

26.9

177

30.4

1

 

44

24.2

180

31.5

1

 

49

27.4

158

30.4

1

 

40

32.8

63

28.1

1

 

 2

84

48.0

304

52.1

1.03 (0.72–1.48)

 

87

47.8

298

52.2

1.15 (0.80–1.65)

 

91

50.8

266

51.3

1.08 (0.76–1.52)

 

54

44.3

114

50.9

0.83 (0.55–1.25)

 

 3

44

25.1

102

17.5

1.44 (0.95–2.17)

 

51

28.0

93

16.3

1.8 (1.20–2.70)

 

39

21.8

95

18.3

1.23 (0.81–1.87)

 

28

23.0

47

21.0

0.96 (0.59–1.56)

 

 No information

3

 

31

   

7

 

27

   

6

 

19

   

6

 

1

   

Start of ART use

 Before pregnancy

41

23.6

102

17.1

1

 

42

22.7

101

17.4

1

 

32

17.6

101

19.2

1

 

23

18.7

76

34.1

1

1

 During pregnancy

133

76.4

495

82.9

0.74 (0.52–1.05)

 

143

77.3

480

82.6

0.78 (0.55–1.10)

 

150

82.4

424

80.8

1.09 (0.74–1.59)

 

100

81.3

147

65.9

1.74 (1.11–2.74)

1.5 (0.71–3.18)

 No information

4

 

17

   

4

 

17

   

3

 

13

   

5

 

2

   

Time of ART use during pregnancy

 <=15 days

1

1.0

7

2.2

1

 

2

1.9

6

1.9

1

 

1

1.2

7

2.3

1

 

1

1.5

4

1.9

1

 

 >15 days

97

99.0

307

97.8

1.92 (0.27–13.77)

 

102

98.1

302

98.1

1.01 (0.25–4.09)

 

84

98.8

295

97.7

1.77 (0.25–12.73)

 

67

98.5

206

98.1

1.23 (0.17–8.84)

 

 No information

80

 

300

   

85

 

290

   

100

 

236

   

60

 

15

   

NRTI

 AZT

158

303.8

550

252.3

1

 

171

275.8

533

260.0

1

 

174

98.9

473

92.9

1

1

101

84.2

194

91.5

1

 

 TDF

7

13.5

32

14.7

0.8 (0.41–1.60)

 

6

9.7

32

15.6

0.65 (0.29–1.47)

 

2

1.1

36

7.1

0.2 (0.05–0.79)

0.21 (0.05–0.83)

19

15.8

18

8.5

1.5 (0.92–2.45)

 

 No information

13

 

32

   

12

 

33

   

9

 

29

   

8

 

13

   

ART during pregnancy

 NRTI+ NRTI + NVP

28

17.4

110

19.7

1

 

34

20.0

103

18.9

1

 

38

4.1

79

2.9

1

 

20

2.6

3

0.2

1

1

 NRTI+ NRTI + NFV

24

14.9

108

19.4

0.9 (0.52–1.55)

 

28

16.5

102

18.8

0.87 (0.53–1.43)

 

33

3.6

87

3.2

0.85 (0.53–1.35)

 

28

3.6

3

0.2

1.04 (0.59–1.84)

0.95 (0.5–1.81)

 NRTI+ NRTI + LPV/R

104

64.6

318

57.1

1.22 (0.80–1.84)

 

103

60.6

319

58.6

0.98 (0.67–1.45)

 

92

9.9

307

11.4

0.71 (0.49–1.04)

 

63

8.2

198

14.7

0.28 (0.17–0.46)

0.39 (0.19–0.79)

 NRTI+ NRTI + ATV/R

5

3.1

21

3.8

0.95 (0.37–2.46)

 

5

2.9

20

3.7

0.81 (0.32–2.06)

 

2

0.2

22

0.8

0.26 (0.06–1.06)

 

5

0.7

15

1.1

0.29 (0.11–0.77)

0.48 (0.14–1.62)

 No information

17

 

57

   

19

 

54

   

20

 

43

   

12

 

6

   

Birht weight

 >=2500 g

            

139

75.5

427

79.4

1

 

99

78.0

177

78.7

1

 

 <2500 g

            

45

24.5

111

20.6

1.18 (0.84–1.64)

 

28

22.0

48

21.3

1.03 (0.68–1.56)

 

 No information

            

1

 

0

   

1

 

0

   

Gestational age at birth

 >=37 weeks

            

126

68.5

428

80.0

1

1

104

81.9

171

76.3

1

 

 <37 weeks

            

58

31.5

107

20.0

1.55 (1.13–2.11)

1.44 (1.04–1.99)

23

18.1

53

23.7

0.8 (0.51–1.26)

 

 No information

            

1

 

3

   

1

 

1

   

Mode of delivery

 Vaginal

21

11.8

32

5.2

1.87 (1.18–2.94)

1.96 (1.09–3.52)

22

11.6

29

4.8

1.90 (1.22–2.97)

1.43 (0.85–2.39)

10

5.4

36

6.7

0.84 (0.45–1.59)

 

12

9.4

9

4

1.64 (0.90–2.96)

 

 Cesarean

157

88.2

582

94.8

1

1

167

88.4

569

95.2

1

1

175

94.6

502

93.3

1

 

116

90.6

216

96

  

Preterm labor

 No

134

75.7

541

88.7

1

1

123

65.4

551

92.8

1

1

151

81.6

466

87.3

1

 

115

90.6

187

83.5

1

 

 Yes

43

24.3

69

11.3

1.93 (1.37–2.73)

2.08 (1.34–3.24)

65

34.6

43

7.2

3.30 (2.44–4.45)

3.33 (2.43–4.54)

34

18.4

68

12.7

1.36 (0.94–1.98)

 

12

9.4

37

16.5

0.64 (0.36–1.17)

 

 No information

1

 

4

   

1

 

4

   

0

 

4

   

1

 

1

   
  1. ART antiretroviral therapy, NRTI nucleos(t)ide reverse transcriptase inhibitors, AZT zidovudine, TDF tenofovir, NVP nevirapine, NFV nelfinavir, LPV lopinavir, ATV atazanavir, R ritonavir, CDC Centers for Disease Control and Prevention
  2. *Cox Logistic Regression